ONCAlert | 2018 ASCO Annual Meeting

Potential Impact of Regorafenib in Patients With HCC

Ghassan K. Abou-Alfa, MD
Published Online: 9:28 PM, Wed June 15, 2016
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential impact that regorafenib (Stivarga) could have on the treatment landscape of hepatocellular carcinoma (HCC).

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.